

JAST (Journal of Animal Science and Technology) TITLE PAGE
Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
Article Type	Research article
Article Title (within 20 words without abbreviations)	Probiotic strains <i>Bifidobacterium animalis</i> ssp. <i>lactis</i> HY8002 and <i>Lactobacillus plantarum</i> HY7717 improved immunosuppression in cyclophosphamide-treated mice
Running Title (within 10 words)	Combined immunostimulatory effects of HY8002 and HY7717
Author	Ju-Yeon Kim, Joo Yun Kim, Hyeonji Kim, Eun Chae Moon, Keon Heo, Jae-Jung Shim, and Jung-Lyoul Lee
Affiliation	R & BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea
ORCID (for more information, please visit https://orcid.org)	Keon Heo (https://orcid.org/0000-0001-5874-9389)
Competing interests	No potential conflict of interest relevant to this article was reported.
Funding sources State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available.	Not applicable.
Acknowledgements	Not applicable.
Availability of data and material	Upon reasonable request, the datasets of this study can be available from the corresponding author.
Authors' contributions Please specify the authors' role using this form.	Conceptualization: Kim J-Y, Kim JY, Shim J-J, Lee J-L. Data curation: Heo K. Formal analysis: Kim JY. Methodology: Kim J-Y. Software: Kim J-Y. Validation: Kim J-Y, Kim JY. Investigation: Kim J-Y, Kim JY, Kim H, Moon EC. Writing - original draft: Kim J-Y. Writing - review & editing: Kim J-Y, Kim JY, Kim H, Moon EC, Heo K, Shim J-J, Lee J-L.
Ethics approval and consent to participate	IACUC approval number, AEC-2021-0009-Y

CORRESPONDING AUTHOR CONTACT INFORMATION

For the corresponding author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Keon Heo
Email address – this is where your proofs will be sent	gunny@hy.co.kr
Secondary Email address	tripleheo@gmail.com
Address	R & BD Center, hy Co. Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea
Cell phone number	010-3311-4738
Office phone number	070-7835-6040
Fax number	031-8005-7831

1 **Abstract**

2 Previous studies reported that *Bifidobacterium animalis* ssp. *lactis* HY8002 (HY8002) improved intestinal integrity
3 and had immunomodulatory effects. *Lactobacillus plantarum* HY7717 (HY7717) was screened in vitro from among
4 21 other lactic acid bacteria (LAB) and demonstrated nitric oxide (NO) production. The aims of this study were to
5 investigate the individual and combined *ex vivo* and *in vivo* effects of LAB strains HY8002 and HY7717 at
6 immunostimulating mice that have been challenged with an immunosuppressant drug. The combination of HY8002
7 and HY7717 increased the secretion of cytokines such as interferon (IFN)- γ , interleukin (IL)-12, and tumor necrosis
8 factor (TNF)- α in splenocytes. In a mouse cyclophosphamide (CTX)-induced immunosuppression model,
9 administration of the foregoing LAB combination improved the splenic and hematological indices, activated natural
10 killer (NK) cells, and up-regulated plasma immunoglobulins and cytokines. Moreover, this combination treatment
11 increased Toll-like receptor 2 (TLR2) expression. The ability of the combination treatment to upregulate IFN- γ and
12 TNF- α in the splenocytes was inhibited by anti-TLR2 antibody. Hence, the immune responses stimulated by the
13 combination of HY8002 and HY7717 are associated with TLR2 activation. The preceding findings suggest that the
14 combination of the HY8002 and HY7717 LAB strains could prove to be a beneficial and efficacious
15 immunostimulant probiotic supplement. The combination of the two probiotic strains would be applied on dairy
16 products.

17
18 **Keywords:** Immune, Immunostimulation, Cytokines, Toll-like receptor, Cyclophosphamide

19

20 **Introduction**

21 The immune system comprises innate and adaptive immunity. It is a tightly regulated network that maintains
22 homeostasis under normal physiological conditions (1). Lymphocytes and macrophages play vital roles in both types
23 of immunity (2, 3). NK cells are key components of innate immunity and guard the host against tumors and viral
24 infections. T and B lymphocytes are primary effectors in adaptive immunity (4). Activated lymphocytes and
25 macrophages produce inflammatory mediators such as nitric oxide (NO), tumor necrosis factor (TNF)- α , interferon
26 (IFN)- γ , and interleukin (IL)-12 (5-7).

27 Probiotics are living microorganisms that provide various health benefits to the host, and lactic acid bacteria
28 (LAB) such as *Lactobacillus* and *Bifidobacteria* are known as common probiotic bacterial species (8, 9). Particularly,
29 the immunomodulatory efficacy of probiotics has aroused much research interest in recent years (10, 11). However,

30 their effects on the immune system widely vary even among strains within the same species. Hence, characterizing
31 the effects of specific strains and determining their optimal doses and combinations are necessary to validate the
32 health claims (12). Previous studies have demonstrated that LAB-induced immunomodulatory responses are
33 mediated through pattern recognition receptors (PRRs) expressed on immune cells, such as toll-like receptors
34 (TLRs) (13-15). However, even in the same species of LAB, the PRRs mainly involved are different depending on
35 the strain, and the immunomodulatory effect may appear in various ways, such as immunostimulation and
36 immunoregulation (16).

37 Cyclophosphamide (CTX) is an antineoplastic and immunosuppressive drug administered for various cancers and
38 autoimmune diseases (17, 18). However, it produces activated metabolites that interfere with DNA replication and
39 damage mitochondrial and lysosomal membranes, which can injure normal cells as well as cancer cells (19). The
40 CTX-induced cytotoxicity may generate various side effects such as hematological malignancies, infections, and
41 bone marrow depression (20). Hence, researchers have investigated immunoregulatory agents such as functional
42 foods and dietary supplements that mitigate the side effects of chemotherapeutic agents (21).

43 *Bifidobacterium animalis* ssp. *lactis* HY8002 (HY8002) is a probiotic strain confirmed to improve intestinal
44 integrity disturbed by antibiotics (22) and reduce airway hypersensitivity and inflammatory response caused by fine
45 dust (23). Nevertheless, its effect and mechanism on the systemic immune response are unclear. In addition,
46 *Lactobacillus plantarum* HY7717 (HY7717) was selected as a new potential immunostimulatory candidate.
47 Although there have been studies on the immunostimulatory effects of individual strains of probiotics, there is
48 insufficient evidence on the effects of the combination of *Bifidobacterium* and *Lactobacillus* strains on systemic
49 immunity and immunosuppression improvement (24-27). Therefore, we explored possible synergy of efficacy
50 between verified probiotic *Bifidobacterium* strain HY8002 and the newly selected *Lactobacillus* strain HY7717 in
51 mouse primary splenocytes and CTX-induced immunosuppressed mice and aimed to elucidate their molecular
52 mechanisms.

53

54

Materials and Methods

55 *Materials*

56 Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco's modified Eagle minimal essential medium
57 (DMEM), antibiotic-antimycotic, and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY, USA).
58 Griess reagent, levamisole hydrochloride (LH), cyclophosphamide (CTX), concanavalin A (Con A), and

59 lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Enzyme-linked
60 immunosorbent assay (ELISA) kits for IFN- γ , IL-12, and TNF- α were acquired from BD Biosciences (San Diego,
61 CA, USA). ELISA kits for IgA and IgG were procured from Abcam (Cambridge, MA, USA) and Invitrogen
62 (Carlsbad, CA, USA), respectively. Anti-mouse TLR2 monoclonal antibody (mAb) (clone C9A12. No. mabg-mtlr2)
63 and anti-mouse TLR4 mAb (clone MTS510. No. 117617) were obtained from InvivoGen (San Diego, CA, USA)
64 and BioLegend (San Diego, CA, USA), respectively.

65

66 *Bacterial Strain Preparation*

67 LAB strains including *Bifidobacterium animalis* ssp. *lactis* HY8002 and *Lactobacillus plantarum* HY7717 were
68 stored in the seed culture library of hy Co., Ltd. (Yongin, Korea). *Bifidobacterium* strains and *Lactobacillus* strains
69 were anaerobically cultured in blood glucose liver (BL) broth or de Man Rogosa and Sharpe (MRS) broth at 37°C
70 for 18 hours. The cultured LAB strains were centrifuged at 2000 g for 15 min and then resuspended in PBS
71 (phosphate buffered saline) for subsequent experiments

72

73 *Nitric Oxide (NO) Assay*

74 NO release was indirectly detected by measuring stable NO catabolites in cell culture media via the Griess
75 reaction. RAW 264.7 macrophages were plated into 96-well plates at 1×10^4 cells/well and treated with LAB strains
76 (1×10^5 cells/mL) for 24 hours. The cell culture medium was mixed with an equal amount of Griess reagent and left
77 in the dark at room temperature for 15 min. Absorbance was measured at 540 nm and the NO quantity was
78 determined by interpolation of a sodium nitrite standard curve.

79

80 *Cytokine Determination in Splenocyte*

81 Splenocytes were isolated from aseptically collected mouse spleens through a 40 μ m cell strainer, and then plated
82 at 1×10^6 /well in RPMI 1640 medium in a 24-well plate. Each well was treated with 1×10^7 CFU/mL of HY8002,
83 HY7717, or a 1:1 mixture of HY8002 and HY7717, and then cultured at 37°C under 5% CO₂ conditions for 24 to 48
84 hours. Cytokine levels in the culture medium were determined with ELISA kits according to the manufacturer's
85 instructions.

86

87 *RT-qPCR Assay*

88 RNA was extracted using an Easy-BLUE™ Total Extraction kit (iNtRON Biotechnology Inc., Seongnam,
89 Korea). The cDNA was synthesized with an Omniscript® Reverse Transcription kit (Qiagen, Hilden, Germany) on a
90 thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). The mRNA levels were measured using a TaqMan
91 Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and a QuantStudio 6 Real-Time PCR
92 System (Applied Biosystems). The TLR2 (Mm00442346_m1), TLR4 (Mm00445273_m1), and GAPDH
93 (Mm99999915_g1) transcripts were quantified with gene-specific primers.

94

95 *Animal Experiment*

96 Male Balb/c mice (7 weeks; 20–22 g) were obtained from Dooyeol Biotech (Seoul, Korea). The animal facility
97 was maintained at 20–22°C, 40–60% RH, and 12 h light/12 h dark cycle. The mice had ad libitum access to an
98 autoclaved standard laboratory diet and water. All experimental procedures were approved by the Ethics Review
99 Committee of the R&D Center of hy Co. Ltd., Korea (IACUC approval number, AEC-2021-0009-Y). After 1 week
100 adaptation, the mice were divided into six groups (n = 5): normal mice (NOR), CTX, LH (20 mg/kg/day), HY8002
101 (1×10^9 CFU/kg/day), HY7717 (1×10^9 CFU/kg/day), and HY8002+HY7717 (1:1 ratio; 1×10^9 CFU/kg/day). LH,
102 HY8002, and HY7717 were intragastrically administered in sterile saline once daily for 8 day. All mice except those
103 in the NOR group were intraperitoneally injected with 150 mg/kg/day CTX on day 8. At day 10, whole blood was
104 collected in anticoagulant tubes, the plasma was isolated, and the spleens were excised and weighed.

105

106 *Natural Killer Cell Activity Assay*

107 Splenic NK cells were isolated by MACS Cell separate kit with CD49b (DX5) MicroBeads (Miltenyi Biotec
108 Technology, Bergisch Gladbach, Germany), placed in a 96-well round-bottom plate at a density of 1×10^5 cells/well
109 and co-cultured with an equal density of YAC-1 cells for 16 hours. Lactate dehydrogenase (LDH), as an indicator of
110 NK cell cytotoxicity against YAC-1, was measured using a CytoTox® 96 non-radioactive cytotoxicity assay kit
111 (Promega, Madison, WI, USA).

112

113 *Splenocyte Proliferation Assay*

114 Splenocytes were prepared as previously described, plated into 96-well plates at a density of 2×10^5 cells/well,
115 and subjected either to Con A (4 µg/mL) or LPS (1 µg/mL). After 48 hours, cell counting kit-8 (CCK-8) solution
116 was added and absorbances were measured at 450 nm.

117

118 *Complete Blood Cell Count*

119 Blood counts were performed using an auto hematology analyzer (BC-5000 Vet; Mindray, Shenzhen, China).

120

121 *Immunoglobulin and Cytokine Determination in Plasma*

122 Plasma IgA, IgG, and IL-12 levels were measured using ELISA kits according to the manufacturer's instructions.

123

124 *Statistical Analysis*

125 Data are represented as means \pm standard deviation (SD) for ≥ 3 independent experiments. Significant
126 differences were identified by one-way analysis of variance (ANOVA) followed by the Newman-Keuls test ($p <$
127 0.05). An unpaired t-test was used to compare means between two independent groups. All statistical analyses were
128 performed using GraphPad Prism v5 (San Diego, CA, USA).

129

130 **Results**

131 *Effects of LAB Strains on NO Production in RAW 264.7 Macrophages*

132 We tested the effects of 252 LAB strains on NO inhibition in RAW 264.7 macrophages. Of these, 21
133 demonstrated anti-inflammatory efficacy (data not shown) and their immunostimulatory function was evaluated. We
134 measured NO concentrations in culture media to determine whether the 21 LAB strains activate RAW 264.7 (Fig. 1).
135 Eleven of the strains increased the relative NO rates by > 30 -fold. Of these, HY7717 showed the largest NO rate
136 increase (45.2-fold).

137

138 *Effects of Combined HY8002 plus HY7717 on Splenocyte Cytokines*

139 We subjected splenocytes to single and combined HY8002 and HY7717 treatments and measured the IFN- γ , IL-
140 12, and TNF- α levels using ELISA (Fig. 2). The cytokine levels in the splenocytes treated with all LAB strains were
141 significantly higher than those in the vehicle control. Cytokine secretion was significantly higher in response to all
142 combination treatments than each standalone treatment.

143

144 *Effects of Combined HY8002 and HY7717 Administration on Splenic and Hematological Indices of* 145 *Immunosuppressed Mice*

146 HY8002, HY7717, or a mixture of both was administered to CTX-immunosuppressed mice to assess the
147 immunostimulatory efficacy of LAB strains under physiological conditions. The CTX treatment markedly reduced
148 the spleen index (Fig. 3A). The spleen indices were significantly higher in the LH and HY8002+HY7717 groups
149 than the CTX group. Oral administration of each strain alone non-significantly increased the spleen indices. We also
150 measured the CBC parameters in each group (Fig. 3B–D). Compared with the NOR group, the WBC and RBC
151 counts and Lymph% in the CTX group were significantly reduced by 36.4%, 79.4%, and 29.9%, respectively. LH
152 administration significantly increased the relative WBC count and Lymph% but not the RBC count. The HY8002,
153 HY7717, and HY8002+HY7717 groups presented with significantly higher WBC counts than the CTX group. The
154 HY8002+HY7717 group presented with significantly higher Lymph% and RBC counts than the CTX group.
155 However, the HY8002 and HY7717 groups presented with non-significantly higher Lymph% and RBC counts than
156 the CTX group.

157

158 *Effects of Combined HY8002 and HY7717 Administration on NK Cell Activity and Splenocyte Proliferation in* 159 *Immunosuppressed Mice*

160 NK cell activity and T and B cell proliferation were assessed for the spleens of all treatment groups. The CTX
161 treatment significantly decreased NK cell cytotoxicity against its YAC-1 target cell (Fig. 4). However, the LH
162 treatment restored NK cell activity. All LAB treatments significantly increased NK cell activity. However, the
163 combination treatments were significantly more efficacious than the single treatments. Splenic lymphocytes were
164 incubated with Con A and LPS to evaluate T and B lymphocyte proliferation, respectively (Fig. 5). LH reversed
165 CTX-induced inhibition of T and B lymphocyte proliferation. Standalone HY8002 and HY7717 and their
166 combination significantly increased T and B lymphocyte proliferation compared with the CTX group. Moreover,
167 combined LAB strain administration significantly enhanced T and B lymphocyte proliferation compared with each
168 standalone LAB treatment.

169

170 *Effects of Combined HY8002 and HY7717 Administration on Immunoglobulins and Cytokines in Immunosuppressed* 171 *Mice*

172 We quantified the relative plasma IgA and IgG levels (Fig. 6). Oral LH administration significantly increased IgA
173 and IgG reduced by CTX treatment. No standalone LAB strain significantly altered the IgA levels whereas the
174 combinations did significantly raise them. All LAB treatments significantly increased the IgG levels compared with

175 the CTX group. However, the combination treatments significantly and more effectively increased the IgG levels
176 than the standalone treatments. We measured IFN- γ and IL-12 secretion in cultured Con A- or LPS-stimulated
177 splenic lymphocytes (Fig. 7A–D). The LH and HY8002+HY7717 treatments increased the cytokine levels reduced
178 by the CTX treatments in the Con A-activated T lymphocytes and the LPS-activated B lymphocytes. The cytokine
179 levels in the Con A-activated T lymphocytes of HY8002+HY7717 group were significantly higher than those of
180 standalone LAB groups. The IFN- γ levels in the LPS-activated B lymphocytes of HY7717 or HY8002+HY7717
181 groups were significantly higher than those of CTX group. Only HY8002+HY7717 administration significantly
182 increased the relative IL-12 levels in the LPS-activated B lymphocytes. The HY8002, HY7717, HY8002+HY7717,
183 and LH treatments recovered the plasma IL-12 levels reduced by CTX treatment (Fig. 7E).

184

185 *Toll-like Receptor2-Mediated Cytokine Responses in Splenocytes Subjected to the HY8002 and HY7717* 186 *Combination*

187 TLR2/4 mRNA expression levels in splenocytes treated with single and combined HY8002 and HY7717 were
188 measured to determine whether the immunostimulant efficacy of these LAB is associated with TLRs (Fig. 8A and
189 8B). Each standalone LAB strain slightly upregulated TLR2 mRNA but the combination treatment significantly
190 upregulated it. The HY7717 treatment non-significantly upregulated TLR4 mRNA. After pretreatment with anti-
191 TLR2 or anti-TLR4 antibodies, the IFN- γ , IL-12, and TNF- α levels were measured in the culture media of
192 splenocytes subjected to HY8002, HY7717, or their combination (Fig. 8C–E). Anti-TLR2 or anti-TLR4 antibody
193 alone had no significant inhibitory effect on the cytokine levels. Splenocytes blocked with anti-TLR2 antibody
194 secreted significantly less IFN- γ and TNF- α than those also treated with LAB. Anti-TLR4 antibody blocked IFN- γ
195 and TNF- α production only in the HY7717-treated splenocytes. However, neither antibody had any significant effect
196 on IL-12 secretion.

197

198

Discussion

199 There has been growing interest in the immunomodulatory potential of probiotics in the prevention and treatment
200 of various complex symptoms (28). Several lactic acid bacteria (LAB) strains demonstrated health benefits by
201 enhancing the immune system (29-31). Certain LAB strains regulate T cell effector functions, enhance humoral
202 immunity, and activate lymphocytes and macrophages (32). Our previous work showed that the number of IFN- γ -
203 secreting T cells was increased by co-culturing them with *Bifidobacterium animalis* ssp. *lactics* HY8002-treated

204 dendritic cells (33). Nevertheless, the immunostimulatory properties of HY8002 have not been thoroughly
205 investigated. Here, we discovered that *Lactobacillus plantarum* HY7717 is a potential immunomodulatory agent and
206 evaluated its immunostimulatory efficacy alone and in combination with HY8002 both *ex vivo* and *in vivo*.

207
208 Spleen is a significant organ in terms of understanding immune cell subpopulations and their immune responses
209 to antigens. Splenocytes include T and B cells, macrophages, and natural killer (NK) cells (34). Their immune
210 responses include antigen presentation, T lymphocyte activation, and B lymphocyte differentiation (35). Cytokines
211 control immune cell proliferation and activity. Proinflammatory cytokines such as IFN- γ , IL-12, and TNF- α
212 augment inflammatory responses (12). IFN- γ is produced mainly by T and NK cells and activates macrophages,
213 neutrophils, and other NK cells (36). IL-12 is a heterodimeric protein released from antigen-presenting cells (APCs)
214 such as dendritic cells, macrophages, and B cells and it activates NK and T cells (37). TNF- α is produced mainly by
215 activated macrophages, T cells, and NK cells and promotes inflammatory activity in macrophages (38). Here,
216 HY8002 and HY7717 stimulated IFN- γ , IL-12, and TNF- α production in splenocytes. Moreover, the combination of
217 HY8002 and HY7717 effectively increased cytokine production.

218
219 The mouse cyclophosphamide (CTX)-induced immunosuppression model is widely used to investigate
220 immunomodulatory activity. CTX inhibits the immune response by inactivating immune cells and decreasing
221 proinflammatory cytokine production (39). Here, we investigated the immunomodulatory properties of HY8002 and
222 HY7717 in a mouse CTX-induced immunosuppression model. Levamisole hydrochloride (LH) is
223 immunostimulatory, has several adverse effects, and was used as the positive control (40, 41). As the spleen is a
224 major organ in the immune system, its size is a vital indicator of health and disease (42). Moreover, changes in the
225 lymphocyte count are used to diagnose immune-mediated disease (43). Recent studies showed that red blood cells
226 (RBCs) modulate immune cell activity and maturation (44, 45). In the present study, we confirmed that CTX
227 induced immunosuppression by reducing spleen and hematological indices and verified that administration of a
228 combination of HY8002 and HY7717 increased these indices and counteracted the negative effects of CTX.

229
230 NK cells mediate antitumor and antiviral immune responses (46), by recognizing infected cells in the absence of
231 major histocompatibility complex (MHC) and enable rapid immune responses. T and B lymphocyte proliferation is
232 vital in adaptive immune system activation, and their proliferation in response to mitogens has been widely applied

233 to evaluate the sensitivity of these cells (47). Here, HY8002 and HY7717 effectively enhanced NK cell activity and
234 T and B cell proliferation in CTX-treated mice.

235

236 Immunoglobulin A (IgA) is the first-line defense against infection while IgG is the major antibody in secondary
237 responses. Proinflammatory cytokines play crucial roles in inflammation as a host defense mechanism.
238 Inflammatory responses are beneficial when cytokines are secreted at appropriate level (36). In the present study, a
239 combination of HY8002 and HY7717 upregulated IgA and IgG in CTX-treated mice. It also increased IFN- γ and
240 IL-12 secretion in Con A-activated T cells more than either treatment alone. The foregoing combination also
241 increased IFN- γ and IL-12 production by LPS-activated B cells. Plasma IL-12 levels were higher in response to this
242 combination than either treatment alone. Therefore, administration of HY8002 plus HY7717 resisted
243 immunosuppression *in vivo*.

244

245 Toll-like receptors (TLRs) modulate both innate and adaptive immunity. Certain TLRs are co-stimulatory and
246 increase proliferation and cytokine production in T cells stimulated by their respective ligands (48). Another study
247 demonstrated that TLR signaling is implicated in cytokine production by B cells, antigen presentation, Ig class
248 switching, and B cell survival (49). The bioactive factors and microbe-associated molecular patterns (MAMPs)
249 produced by different LAB strains activate TLR2 (14, 50) Administration of certain LAB strains increased the
250 relative numbers of TLR4⁺ and TLR2⁺ cells produced by mice (51). Here, we investigated whether TLRs mediate
251 HY8002 and HY7717 immune responses. The TLR2 mRNA expression levels increased in healthy splenocytes in
252 response to a combination of HY8002 plus HY7717. By contrast, none of the treatments significantly modulated the
253 TLR4 mRNA expression levels. We demonstrated that anti-TLR2 antibody blocked LAB-induced IFN- γ and TNF- α
254 secretion but had no inhibitory effect on IL-12. Thus, the immune responses of HY8002 and HY7717 may be
255 associated with pattern recognition receptors (PRRs) such as other TLRs or NOD-like receptors (NLRs) (52). TLR2
256 is a major receptor of both HY8002 and HY7717 and promotes immune activity in splenocytes. Weaning stress in
257 piglets can suppress systemic immune responses, making piglets vulnerable to infectious diseases, including
258 diarrhea. Jing Wang et al. reported that the supply of *Lactobacillus plantarum* improves intestinal health in weaned
259 pigs by increasing the expression of host defense peptide (HDP) through TLR2 signaling (53). Since HY7717 and
260 HY8002 have the effect of improving systemic immunosuppression, they are expected to be effective in improving
261 the immune load caused by weaning stress in piglets (54). However, it may not be the sole receptor involved in this

262 process. Therefore, further studies are needed on factors other than TLRs that may influence HY8002 and HY7717-
263 mediated immune responses.

264

265 In this study, the combination of *Bifidobacterium animalis* ssp. *lactics* HY8002 and *Lactobacillus plantarum*
266 HY7717 was more efficacious than either treatment alone at stimulating cytokine release in mouse primary
267 splenocytes. HY8002 plus HY7717 effectively rehabilitated the splenic and hematological indices, NK cell activity,
268 T and B cell proliferation, and immunoglobulin and cytokine production in a mouse CTX-induced
269 immunosuppression model. The immunostimulatory effects of HY8002 and HY7717 were closely associated with
270 TLR2. Hence, the combination of HY8002 and HY7717 effectively enhances immune function, suggesting the
271 possibility of this combination as a probiotics for immune enhancement. Collectively, the combination of the two
272 probiotics would be considered a potential candidate to application of functional dairy foods.

273

274

Acknowledgments

275 Not applicable.

276

277

278

References

- 279 1. Crimeen-Irwin B, Scalzo K, Gloster S, Mottram P, Plebanski M. Failure of immune homeostasis-the
280 consequences of under and over reactivity. *CURRENT DRUG TARGETS-IMMUNE ENDOCRINE AND*
281 *METABOLIC DISORDERS*-. 2005;5(4):413. <https://doi.org/10.2174/156800805774912980>
- 282 2. Eghrari-Sabet JS, Hartley A. Sweet's syndrome: an immunologically mediated skin disease? *Annals of allergy*.
283 1994;72(2):125-8.
- 284 3. Jung JY, Shin JS, Lee SG, Rhee YK, Cho CW, Hong HD, et al. *Lactobacillus sakei* K040706 evokes
285 immunostimulatory effects on macrophages through TLR 2-mediated activation. *International*
286 *immunopharmacology*. 2015;28(1):88-96. <https://doi.org/10.1016/j.intimp.2015.05.037>
- 287 4. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The
288 example of natural killer cells. *Science*. 2011;331(6013):44-9. <https://doi.org/10.1126/science.1198687>
- 289 5. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases.
290 *Frontiers in immunology*. 2014;5:491. <https://doi.org/10.3389/fimmu.2014.00491>
- 291 6. Moncada S. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol rev*. 1991;43:109-42.
- 292 7. Ghosh S, May MJ, Kopp EB. NF- κ B and Rel proteins: evolutionarily conserved mediators of immune
293 responses. *Annual review of immunology*. 1998;16(1):225-60.
294 <https://doi.org/10.1146/annurev.immunol.16.1.225>
- 295 8. Seminario-Amez M, Lopez-Lopez J, Estrugo-Devesa A, Ayuso-Montero R, Jane-Salas E. Probiotics and oral
296 health: A systematic review. *Medicina oral, patologia oral y cirugia bucal*. 2017;22(3):e282-e8.
297 <https://doi.org/10.4317/medoral.21494>
- 298 9. Singh K, Rao A. Probiotics: A potential immunomodulator in COVID-19 infection management. *Nutrition*
299 *research*. 2021;87:1-12. <https://doi.org/10.1016/j.nutres.2020.12.014>
- 300 10. Popova M, Molimard P, Courau S, Crociani J, Dufour C, Le Vacon F, et al. Beneficial effects of probiotics in
301 upper respiratory tract infections and their mechanical actions to antagonize pathogens. *Journal of applied*
302 *microbiology*. 2012;113(6):1305-18. <https://doi.org/10.1111/j.1365-2672.2012.05394.x>
- 303 11. Azad MAK, Sarker M, Wan D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. *BioMed*
304 *research international*. 2018;2018:8063647. <https://doi.org/10.1155/2018/8063647>
- 305 12. Nova E, Warnberg J, Gomez-Martinez S, Diaz LE, Romeo J, Marcos A. Immunomodulatory effects of
306 probiotics in different stages of life. *The British journal of nutrition*. 2007;98 Suppl 1:S90-5.
307 <https://doi.org/10.1017/S0007114507832983>

- 308 13. Neish AS. The gut microflora and intestinal epithelial cells: a continuing dialogue. *Microbes and infection*.
309 2002;4(3):309-17. [https://doi.org/10.1016/S1286-4579\(02\)01543-5](https://doi.org/10.1016/S1286-4579(02)01543-5)
- 310 14. Ren C, Cheng L, Sun Y, Zhang Q, de Haan BJ, Zhang H, et al. Lactic acid bacteria secrete toll like receptor 2
311 stimulating and macrophage immunomodulating bioactive factors. *Journal of Functional Foods*.
312 2020;66:103783. <https://doi.org/10.1016/j.jff.2020.103783>
- 313 15. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules:
314 comparison with commensals and pathogens. *Nature reviews Microbiology*. 2010;8(3):171-84.
315 <https://doi.org/10.1038/nrmicro2297>
- 316 16. Ren C, Zhang Q, de Haan BJ, Zhang H, Faas MM, de Vos P. Identification of TLR2/TLR6 signalling lactic
317 acid bacteria for supporting immune regulation. *Scientific reports*. 2016;6:34561.
318 <https://doi.org/10.1038/srep34561>
- 319 17. Xiao J-h, Liang Z-q, Liu A-y, Chen D-x, Xiao Y, Liu J-w, et al. Immunosuppressive activity of polysaccharides
320 from *Cordyceps gunnii* mycelia in mice in vivo/vitro. *Journal of Food Agriculture and Environment*.
321 2004;2(3):69-73.
- 322 18. Wang H, Wang M, Chen J, Tang Y, Dou J, Yu J, et al. A polysaccharide from *Strongylocentrotus nudus* eggs
323 protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. *International*
324 *immunopharmacology*. 2011;11(11):1946-53. <https://doi.org/10.1016/j.intimp.2011.06.006>
- 325 19. Al-Nasser IA. In vivo prevention of cyclophosphamide-induced Ca²⁺ dependent damage of rat heart and liver
326 mitochondria by cyclosporin A. *Comparative Biochemistry and Physiology Part A: Molecular & Integrative*
327 *Physiology*. 1998;121(3):209-14. <https://doi.org/10.1016/j.intimp.2011.06.006>
- 328 20. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. *Lupus*. 2007;16(3):212-6.
329 <https://doi.org/10.1177/0961203306075613>
- 330 21. Wohlgemuth S, Loh G, Blaut M. Recent developments and perspectives in the investigation of probiotic effects.
331 *International journal of medical microbiology : IJMM*. 2010;300(1):3-10.
- 332 22. Kim JY, Bang S-J, Kim J-Y, Choi EJ, Heo K, Shim J-J, et al. The Probiotic Strain *Bifidobacterium animalis*
333 *ssp. lactis* HY8002 Potentially Improves the Mucosal Integrity of an Altered Intestinal Microbial Environment.
334 *Frontiers in microbiology*. 2022;13. <https://doi.org/10.3389/fmicb.2022.817591>
- 335 23. Nam W, Kim H, Bae C, Kim J, Nam B, Lee Y, et al. *Lactobacillus* HY2782 and *Bifidobacterium* HY8002
336 Decrease Airway Hyperresponsiveness Induced by Chronic PM2.5 Inhalation in Mice. *Journal of medicinal*
337 *food*. 2020;23(6):575-83. <https://doi.org/10.1089/jmf.2019.4604>
- 338 24. Jang SE, Joh EH, Lee HY, Ahn YT, Lee JH, Huh CS, et al. *Lactobacillus plantarum* HY7712 ameliorates
339 cyclophosphamide-induced immunosuppression in mice. *Journal of microbiology and biotechnology*.
340 2013;23(3):414-21. <https://doi.org/10.4014/jmb.1210.10010>

- 341 25. Lee H, Ahn YT, Park SH, Park DY, Jin YW, Kim CS, et al. Lactobacillus plantarum HY7712 protects against
342 the impairment of NK-cell activity caused by whole-body gamma-irradiation in mice. Journal of microbiology
343 and biotechnology. 2014;24(1):127-31. <https://doi.org/10.4014/jmb.1307.07001>
- 344 26. Meng Y, Li B, Jin D, Zhan M, Lu J, Huo G. Immunomodulatory activity of Lactobacillus plantarum
345 KLDS1.0318 in cyclophosphamide-treated mice. Food & nutrition research. 2018;62.
346 <https://doi.org/10.29219/fnr.v62.1296>
- 347 27. Shang J, Wan F, Zhao L, Meng X, Li B. Potential Immunomodulatory Activity of a Selected Strain
348 Bifidobacterium bifidum H3-R2 as Evidenced in vitro and in Immunosuppressed Mice. Frontiers in
349 microbiology. 2020;11:2089. <https://doi.org/10.3389/fmicb.2020.02089>
- 350 28. Claes IJ, Segers ME, Verhoeven TL, Dusselier M, Sels BF, De Keersmaecker SC, et al. Lipoteichoic acid is an
351 important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. Microbial Cell Factories.
352 2012;11(1):1-8. <https://doi.org/10.1186/1475-2859-11-161>
- 353 29. Sim I, Park K-T, Kwon G, Koh J-H, Lim Y-H. Probiotic potential of Enterococcus faecium isolated from
354 chicken cecum with immunomodulating activity and promoting longevity in Caenorhabditis elegans. Journal of
355 microbiology and biotechnology. 2018;28(6):883-92. <https://doi.org/10.4014/jmb.1802.02019>
- 356 30. Peng X, Zhang R, Duan G, Wang C, Sun N, Zhang L, et al. Production and delivery of Helicobacter pylori
357 NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity. Scientific reports.
358 2018;8(1):6435. <https://doi.org/10.1038/s41598-018-24879-x>
- 359 31. Jung IS, Jeon MG, Oh DS, Jung YJ, Kim HS, Bae D, et al. Micronized, Heat-Treated Lactobacillus plantarum
360 LM1004 Alleviates Cyclophosphamide-Induced Immune Suppression. Journal of medicinal food.
361 2019;22(9):896-906. <https://doi.org/10.1089/jmf.2018.4378>
- 362 32. Wells JM, editor Immunomodulatory mechanisms of lactobacilli. Microbial cell factories; 2011: BioMed
363 Central. <https://doi.org/10.1186/1475-2859-10-S1-S17>
- 364 33. Park IJ, Lee JH, Kye BH, Oh HK, Cho YB, Kim YT, et al. Effects of Probiotics on the Symptoms and Surgical
365 outcomes after Anterior Resection of Colon Cancer (POSTCARE): A Randomized, Double-Blind, Placebo-
366 Controlled Trial. Journal of clinical medicine. 2020;9(7). <https://doi.org/10.3390/jcm9072181>
- 367 34. Mo S-J, Nam B, Bae C-H, Park S-D, Shim J-J, Lee J-L. Characterization of Novel Lactobacillus paracasei
368 HY7017 Capable of Improving Physiological Properties and Immune Enhancing Effects Using Red Ginseng
369 Extract. Fermentation. 2021;7(4):238. <https://doi.org/10.3390/fermentation7040238>
- 370 35. Whalley K. Brain-spleen link tunes immunity. Nature reviews Neuroscience. 2020;21(7):350-1.
371 <https://doi.org/10.1038/s41577-020-0347-9>
- 372 36. Zhang JM, An J. Cytokines, inflammation, and pain. International anesthesiology clinics. 2007;45(2):27-37.
373 <https://doi.org/10.1097/AIA.0b013e318034194e>

- 374 37. Trinichieri G. Interleukin.-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate
375 resistance and antigen-specific adaptive immunity. *Annu Rev Immunol.* 1995;13:251-76.
376 <https://doi.org/10.1146/annurev.iy.13.040195.001343>
- 377 38. Chu WM. Tumor necrosis factor. *Cancer letters.* 2013;328(2):222-5.
378 <https://doi.org/10.1016/j.canlet.2012.10.014>
- 379 39. Mei YX, Chen HX, Zhang J, Zhang XD, Liang YX. Protective effect of chitooligosaccharides against
380 cyclophosphamide-induced immunosuppression in mice. *International journal of biological macromolecules.*
381 2013;62:330-5. <https://doi.org/10.1016/j.ijbiomac.2013.09.038>
- 382 40. Fu Y, Wang T, Xiu L, Shi X, Bian Z, Zhang Y, et al. Levamisole promotes murine bone marrow derived
383 dendritic cell activation and drives Th1 immune response in vitro and in vivo. *International*
384 *immunopharmacology.* 2016;31:57-65. <https://doi.org/10.1016/j.intimp.2015.12.015>
- 385 41. Yin J, Jin H, Yang F, Ding Z, Huang C, Zhu Q, et al. Synergistic effects of adjuvants interferon-gamma and
386 levamisole on DNA vaccination against infection with Newcastle disease virus. *Viral immunology.*
387 2007;20(2):288-99. <https://doi.org/10.1089/vim.2006.0108>
- 388 42. Park H-E, Lee W-K. Immune enhancing effects of *Weissella cibaria* JW15 on BALB/c mice
389 immunosuppressed by cyclophosphamide. *Journal of Functional Foods.* 2018;49:518-25.
390 <https://doi.org/10.1016/j.jff.2018.09.003>
- 391 43. Cheng VC, Hung IF, Wu AK, Tang BS, Chu CM, Yuen KY. Lymphocyte surge as a marker for
392 immunorestitution disease due to *Pneumocystis jirovecii* pneumonia in HIV-negative immunosuppressed hosts.
393 *European journal of clinical microbiology & infectious diseases* : official publication of the European Society
394 of Clinical Microbiology. 2004;23(6):512-4. <https://doi.org/10.1007/s10096-004-1140-6>
- 395 44. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signalling and modulating immune
396 cells. *Blood reviews.* 2020;41:100644. <https://doi.org/10.1016/j.blre.2019.10064>
- 397 45. Minton K. Red blood cells join the ranks as immune sentinels. *Nature Reviews Immunology.* 2021;21(12):760-
398 1. <https://doi.org/10.1038/s41577-021-00648-2>
- 399 46. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical
400 Utilization. *Frontiers in immunology.* 2018;9:1869. <https://doi.org/10.3389/fimmu.2018.01869>
- 401 47. Meng M, Wang H, Li Z, Guo M, Hou L. Protective effects of polysaccharides from *Cordyceps gunnii* mycelia
402 against cyclophosphamide-induced immunosuppression to TLR4/TRAF6/NF-kappaB signalling in BALB/c
403 mice. *Food & function.* 2019;10(6):3262-71. <https://doi.org/10.1039/C9FO00482C>
- 404 48. Oberg HH, Juricke M, Kabelitz D, Wesch D. Regulation of T cell activation by TLR ligands. *European journal*
405 *of cell biology.* 2011;90(6-7):582-92. <https://doi.org/10.1016/j.ejcb.2010.11.012>


- 406 49. Hua Z, Hou B. TLR signaling in B-cell development and activation. *Cellular & molecular immunology*.
407 2013;10(2):103-6. <https://doi.org/10.1038/cmi.2012.61>
- 408 50. Owens JA, Saeedi BJ, Naudin CR, Hunter-Chang S, Barbian ME, Eboka RU, et al. *Lactobacillus rhamnosus*
409 GG orchestrates an antitumor immune response. *Cellular and Molecular Gastroenterology and Hepatology*.
410 2021;12(4):1311-27. <https://doi.org/10.1016/j.jcmgh.2021.06.001>
- 411 51. Castillo NA, Perdigón G, de Moreno de LeBlanc A. Oral administration of a probiotic *Lactobacillus* modulates
412 cytokine production and TLR expression improving the immune response against *Salmonella enterica* serovar
413 Typhimurium infection in mice. *BMC microbiology*. 2011;11(1):1-12. <https://doi.org/10.1186/1471-2180-11-177>
414
- 415 52. Cortes-Perez NG, de Moreno de LeBlanc A, Gomez-Gutierrez JG, LeBlanc JG, Bermúdez-Humarán LG.
416 Probiotics and Trained Immunity. *Biomolecules*. 2021;11(10):1402. <https://doi.org/10.3390/biom11101402>
- 417 53. Campbell JM, Crenshaw JD, Polo J. The biological stress of early weaned piglets. *Journal of animal science*
418 and biotechnology. 2013;4(1):1-4. <https://doi.org/10.1186/2049-1891-4-19>
- 419 54. Wang J, Zhang W, Wang S, Liu H, Zhang D, Wang Y, et al. Swine-derived probiotic *Lactobacillus plantarum*
420 modulates porcine intestinal endogenous host defense peptide synthesis through TLR2/MAPK/AP-1 signaling
421 pathway. *Frontiers in immunology*. 2019;10:2691. <https://doi.org/10.3389/fimmu.2019.02691>

422

423

424

Tables and Figures




425

426 **Fig. 1. Effects of HY7717 on NO production in RAW 264.7 macrophages.** Cells were treated with 21 different

427 Lactobacillus strains at 1.0×10^5 CFU/0.1 mL for 24 h. NO was detected in the culture media using the Griess assay.

428 Data represent fold changes in NO production compared with untreated cells.

429




431
432
433

Fig. 2. Combined effects of HY8002 and HY7717 on cytokine production in mouse splenocytes. (A–C)


434 Splenocytes isolated from normal mice were treated with HY8002, HY7717, their combination (1.0×10^7 CFU/mL)
435 or LPS ($1 \mu\text{g/mL}$) for 24 h. The amounts of IFN- γ , IL-12, and TNF- α released into the culture media were measured
436 using ELISA kits. Data are represented as means \pm SD of three independent experiments. * $p < 0.05$, ** $p < 0.01$, and
437 *** $p < 0.001$ compared with the vehicle group. † $p < 0.05$, †† $p < 0.01$, and ††† $p < 0.001$ compared with the
438 combination treatment.

439




441
 442 **Fig. 3. Combined effects of orally administered HY8002 and HY7717 on spleen weight and hematological**
 443 **indices in CTX-immunosuppressed mice.** (A) The spleen index was calculated as [index = spleen weight (mg) /
 444 body weight (g)]. (B–D) Blood was collected to determine complete blood cell count. Data are means \pm SD (n = 5).
 445 ### $p < .001$ compared with the normal group. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared with the CTX-
 446 induced group. † $p < 0.05$ and †† $p < 0.01$ compared with the combination treatment.

447




449
 450 **Fig. 4. Combined effects of orally administered HY8002 and HY7717 on NK cell activity in CTX-**
 451 **immunosuppressed mice.** Data are means \pm SD (n = 5). ### $p < .001$ compared with the NOR group. ** $p < 0.01$ and
 452 *** $p < 0.001$ compared with the CTX group. †† $p < 0.01$ compared with the combination treatment.


453



455
 456 **Fig. 5. Combined effects of orally administered HY8002 and HY7717 on splenocyte proliferation in CTX-**
 457 **immunosuppressed mice.** (A, B) Mouse splenocytes were stimulated with Con A (4 $\mu\text{g}/\text{mL}$) or LPS (1 $\mu\text{g}/\text{mL}$) for
 458 48 h. Data are means \pm SD (n = 5). ### $p < 0.001$ compared with the NOR group. ** $p < 0.01$ and *** $p < 0.001$
 459 compared with the CTX group. $\dagger\dagger p < 0.01$ compared with the combination treatment.




462
 463 **Fig. 6. Combined effects of orally administered HY8002 and HY7717 on immunoglobulin levels in CTX-**
 464 **immunosuppressed mice.** (A, B) Plasma IgA and IgG levels were assayed using ELISA kits. Data are represented
 465 as means \pm SD (n = 5). # $p < 0.05$ and ### $p < 0.001$ compared with the NOR group. * $p < 0.05$, ** $p < 0.01$, and *** $p <$
 466 0.001 compared with the CTX group. † $p < 0.05$ compared with the combination treatment.



467

468 **Fig. 7. Combined effects of orally administered HY8002 plus HY7717 on cytokine production in CTX-**
 469 **immunosuppressed mice.** (A, B) Mouse splenocytes were stimulated with Con A (4 μ g/mL) for 48 h. IFN- γ (A)
 470 and IL-12 (B) levels in the culture medium were detected with ELISA kits. (C, D) Mouse splenocytes were
 471 stimulated with LPS (1 μ g/mL) for 48 h. IFN- γ (C) and IL-12 (D) levels in the culture medium were detected with
 472 ELISA kits. (E) Plasma IL-12 levels were assessed using an ELISA kit. # $p < 0.05$ and ### $p < 0.001$ compared with
 473 the NOR group. * $p < 0.05$ and *** $p < 0.001$ compared with the CTX group. † $p < 0.05$, †† $p < 0.01$, and ††† $p < 0.001$
 474 compared with the combination treatment.



475

476 **Fig. 8. Effects of HY8002 or HY7717 on TLR2-mediated cytokine production in mouse splenocytes.** (A, B)

477 Splenocytes isolated from normal mice were treated with HY8002, HY7717, or their combination (1.0×10^7

478 CFU/mL). Relative mRNA levels of TLR2 (A) and TLR4 (B) were normalized against that of GAPDH. (C–E)

479 Mouse splenocytes were pretreated with anti-TLR2 or anti-TLR4 mAb for 1 h followed by HY8002, HY7717, or

480 their combination treatment for 24 h. IFN- γ (C), IL-12 (D), and TNF- α (E) secretion in the culture media was

481 determined with ELISA kits. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ for pairwise treatment group comparisons. No

482 Ab, Non-treated antibody; TLR2 Ab, Toll-like receptor 2 antibody; TLR4 Ab, Toll-like receptor 4 antibody.